Literature DB >> 33486672

Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player.

Paula Pennanen1, Roope A Kallionpää1, Sirkku Peltonen2,3,4, Liisa Nissinen2,5, Veli-Matti Kähäri2,5, Eetu Heervä6, Juha Peltonen7.   

Abstract

Little is known about the signaling pathways involved in the differentiation of human osteoclasts. The present study evaluated the roles of the Ras/PI3K/Akt/mTOR, Ras/Raf/MEK1/2/ERK1/2, calcium-PKC, and p38 signaling pathways in human osteoclast differentiation. Mononuclear cells were isolated from the peripheral blood of control persons and patients with neurofibromatosis 1 (NF1), and the cells were differentiated into osteoclasts in the presence of signaling pathway inhibitors. Osteoclast differentiation was assessed using tartrate-resistant acid phosphatase 5B. Inhibition of most signaling pathways with chemical inhibitors decreased the number of human osteoclasts and disrupted F-actin ring formation, while the inhibition of p38 resulted in an increased number of osteoclasts, which is a finding contradictory to previous murine studies. However, the p38 inhibition did not increase the bone resorption capacity of the cells. Ras-inhibitor FTS increased osteoclastogenesis in samples from control persons, but an inhibitory effect was observed in NF1 samples. Inhibition of MEK, PI3K, and mTOR reduced markedly the number of NF1-deficient osteoclasts, but no effect was observed in control samples. Western blot analyses showed that the changes in the phosphorylation of ERK1/2 correlated with the number of osteoclasts. Our results highlight the fact that osteoclastogenesis is regulated by multiple interacting signaling pathways and emphasize that murine and human findings related to osteoclastogenesis are not necessarily equivalent.

Entities:  

Keywords:  ERK1/2; Neurofibromatosis 1; Osteoclast; Signaling pathways; p38

Mesh:

Substances:

Year:  2021        PMID: 33486672      PMCID: PMC7925492          DOI: 10.1007/s11033-020-06128-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

1.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

2.  Rapamycin and mTOR kinase inhibitors.

Authors:  Lisa M Ballou; Richard Z Lin
Journal:  J Chem Biol       Date:  2008-05-15

Review 3.  Colony-stimulating factor-1 receptor.

Authors:  C J Sherr
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

Review 4.  Mammalian target of rapamycin as a therapeutic target in osteoporosis.

Authors:  Gengyang Shen; Hui Ren; Ting Qiu; Zhida Zhang; Wenhua Zhao; Xiang Yu; Jinjing Huang; Jingjing Tang; Zhensong Yao; Zhidong Yang; Xiaobing Jiang
Journal:  J Cell Physiol       Date:  2017-09-28       Impact factor: 6.384

Review 5.  Neurofibromatosis type 1.

Authors:  David H Gutmann; Rosalie E Ferner; Robert H Listernick; Bruce R Korf; Pamela L Wolters; Kimberly J Johnson
Journal:  Nat Rev Dis Primers       Date:  2017-02-23       Impact factor: 52.329

6.  Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.

Authors:  E Aizman; E Blacher; O Ben-Moshe; T Kogan; Y Kloog; A Mor
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

7.  Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.

Authors:  Iris Breitkreutz; Marc S Raab; Sonia Vallet; Teru Hideshima; Noopur Raje; Dharminder Chauhan; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

Review 8.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

Authors:  S Vasikaran; R Eastell; O Bruyère; A J Foldes; P Garnero; A Griesmacher; M McClung; H A Morris; S Silverman; T Trenti; D A Wahl; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2010-12-24       Impact factor: 4.507

9.  PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β.

Authors:  Jihye Shin; Hyunduk Jang; Jingjing Lin; Soo Young Lee
Journal:  Mol Cells       Date:  2014-09-26       Impact factor: 5.034

10.  BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.

Authors:  Yvonne Kuma; Guadalupe Sabio; Jenny Bain; Natalia Shpiro; Rodolfo Márquez; Ana Cuenda
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

View more
  2 in total

1.  Cholesterol inhibits autophagy in RANKL-induced osteoclast differentiation through activating the PI3K/AKT/mTOR signaling pathway.

Authors:  Chunyan Jiang; Yan Wang; Mengqi Zhang; Jin Xu
Journal:  Mol Biol Rep       Date:  2022-07-26       Impact factor: 2.742

2.  Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway.

Authors:  Jiahao Zhang; Liang Mo; Haoran Huang; Jiake Xu; Yinuo Fan; Weifeng Li; Haibin Wang; Chi Zhou; Hanjun Fang; Wei He; Zhenqiu Chen; Yuhao Liu
Journal:  Sci Rep       Date:  2022-08-23       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.